Comparing Liposomal Bupivacaine and BupivacaineEpinephrine plus Dexamethasone for Pain Relief After Robotic Lung Surgery

What this Trial Is About

Researchers are evaluating pain control methods following robotic lung surgery. This prospective randomized single-blinded clinical trial compares two approaches wound infiltration and intercostal nerve block using either liposomal bupivacaine or a combination of bupivacaineepinephrine plus dexamethasone. Liposomal bupivacaine is a newer local anesthetic that has not yet been compared to the established bupivacaineepinephrine plus dexamethasone combination in this surgical context. Participants will be randomly assigned to one of two groups. One group will receive an intercostal nerve block and wound infiltration with 266 mg of liposomal bupivacaine combined with 24 ml of 0.5% bupivacaine. The other group will receive intercostal nerve block and wound infiltration with 42 ml of 0.5% bupivacaineepinephrine plus 8 mg dexamethasone during their robotic lung resection surgery. During the study, participants pain levels will be assessed using the Visual Analogue Scale 24 hours after surgery. Researchers will monitor and compare pain control effectiveness between the two treatments. The trial is led by The Cooper Health System and includes adults aged 18 to 90 undergoing robotic wedge resection or lobectomy for lung masses. The studys design includes randomized allocation and double masking to ensure unbiased results.

Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine